Tirzepatide
FDA-approved dual GIP/GLP-1 agonist producing 22.5% weight loss—the highest ever recorded in an anti-obesity medication trial.
Also known as: Mounjaro, Zepbound, Dual GIP/GLP-1 Agonist
Available on Forge Amino
Tirzepatide — independently lab tested, 99%+ purity, QR-linked COA.
Important: This content is for informational and research purposes only and is not intended for human or veterinary use. Consult your physician for health-related guidance and laboratory monitoring.
How It Works
GIP agonism reduces lipolysis in adipose tissue and appetite via CNS pathways; GLP-1 agonism delays gastric emptying, increases satiety, and suppresses glucagon. Synergistic effect exceeds sum of individual components.
Key Benefits
- ✓22.5% average weight loss at 15 mg
- ✓75% fat loss, 25% lean mass (superior body composition)
- ✓Superior HbA1c control vs semaglutide
- ✓Improved triglycerides and blood pressure
- ✓Once-weekly convenient dosing
Dosing Protocols
Beginner / Intermediate
Dose
2.5-5 mg
Frequency
Once weekly subcutaneous
Cycle Length
12+ weeks
Notes
Standard escalation: 2.5 mg weekly for 4 weeks, then 5 mg
Advanced
Dose
10-15 mg
Frequency
Once weekly subcutaneous
Cycle Length
24-48 weeks
Notes
Escalate 2.5 mg every 4 weeks to maintenance 15 mg
Side Effects & Safety
Common Side Effects
- Nausea (25-35% at escalation)
- Diarrhea (20-25%)
- Vomiting (8-12%)
- Constipation (10-15%)
- Heart rate increase (8-10 bpm)
Contraindications
- Personal or family history of medullary thyroid carcinoma
- MEN2 syndromes
- History of pancreatitis
- Type 1 diabetes (relative)
- DKA history
- ESRD (eGFR <15)
Stacking & Synergies
These compounds have complementary mechanisms and may enhance results when used together.
Key Takeaway
Proven weight loss: Tirzepatide achieves 22.5% fat loss with superior lean mass preservation.
Research Disclaimer: This content is for informational and research purposes only. It is not medical advice. These products are not approved by the FDA for human consumption. Consult a qualified healthcare provider before starting any new protocol. The information provided is based on preclinical research and anecdotal reports and has not been formally evaluated in randomized controlled trials.